Crossmark

Adjunctive therapy with the Tie2 agonist Vasculotide reduces pulmonary permeability in Streptococcus pneumoniae infected and mechanically ventilated mice

Crossref DOI link: https://doi.org/10.1038/s41598-022-19560-3

Published Online: 2022-09-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lask, Aina

Gutbier, Birgitt

Kershaw, Olivia

Nouailles, Geraldine

Gruber, Achim D.

Müller-Redetzky, Holger C.

Chackowicz, Steven

Hamilton, Douglas A.

Van Slyke, Paul

Witzenrath, Martin
Funding

Funding for this research was provided by:

German Research Foundation (SFB-TR84 Z01b, SFB-TR84 C6, C9)

German Federal Ministry of Education and Research German Ministry of Education (CAPSyS (01ZX1304B))

Charité - Universitätsmedizin Berlin
License Information

Text and Data Mining valid from 2022-09-15

Version of Record valid from 2022-09-15
More Information

Article History

Received: 8 December 2021

Accepted: 31 August 2022

First Online: 15 September 2022

Competing interests

: Steven Chackowicz, Doug Hamilton and Paul Van Slyke are named as inventors on several patents related to the Vasculotide technology. Doug Hamilton and Steven Chackowicz are officers in Vasomune Therapeutics. All other authors declare that they have no competing interests.

Document is current

Any future updates will be listed below